These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7704494)

  • 21. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.
    Pisters KM; Kris MG; Gralla RJ; Zaman MB; Heelan RT; Martini N
    J Clin Oncol; 1993 Sep; 11(9):1757-62. PubMed ID: 8394881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial with mitomycin-C/ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small-cell lung cancer.
    Gatzemeier U; Heckmayr M; Hossfeld DK; Kaukel E; Koschel G; Neuhauss R
    Am J Clin Oncol; 1991 Oct; 14(5):405-11. PubMed ID: 1659174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A pilot study of induction chemotherapy with cisplatin, mitomycin C and vindesine for stage III N2 non-small cell lung cancer].
    Nishiwaki Y; Nagai K; Kodama T; Nishiyama H; Hojo H; Matsumoto T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():203-11. PubMed ID: 8007467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.
    Furuse K; Kubota K; Kawahara M; Kodama N; Ogawara M; Akira M; Nakajima S; Takada M; Kusunoki Y; Negoro S
    J Clin Oncol; 1995 Apr; 13(4):869-75. PubMed ID: 7707113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer. A Southwest Oncology Group study.
    Higano CS; Crowley J; Livingston RB; Goodwin JW; Barlogie B; Stuckey WJ
    Cancer; 1991 May; 67(10):2439-42. PubMed ID: 1849785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.
    Takada M; Fukuoka M; Ariyoshi Y; Furuse K; Niitani H; Ota K; Motomiya M; Hasegawa K; Tominaga K; Kuriyama T
    Cancer Chemother Pharmacol; 1992; 31(3):182-6. PubMed ID: 1281446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
    Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T
    Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.
    Kris MG; Gralla RJ; Wertheim MS; Kelsen DP; O'Connell JP; Burke MT; Fiore JJ; Cibas IR; Heelan RT
    Cancer Treat Rep; 1986 Sep; 70(9):1091-6. PubMed ID: 3527408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research.
    Crinò L; Clerici M; Figoli F; Barduagni M; Carlini P; Ceci G; Cortesi E; Carpi A; Santini A; Di Costanzo F
    Lung Cancer; 1995 Apr; 12 Suppl 1():S125-32. PubMed ID: 7551920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.
    Luedke DW; Einhorn L; Omura GA; Sarma PR; Bartolucci AA; Birch R; Greco FA
    J Clin Oncol; 1990 May; 8(5):886-91. PubMed ID: 2159054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of carboplatin, cisplatin, and vindesine in advanced non-small-cell lung cancer.
    Saito H; Shimokata K; Saka H; Yamamoto M; Ogasawara T; Nomura F; Sakai S; Iwata M; Murate T; Miyachi T
    Cancer Chemother Pharmacol; 1993; 33(2):154-6. PubMed ID: 8261575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Rixe O; Gatineau M; Jauffret E; Spano JP; Orcel B; Vannetzel JM; Berille J; Derenne JP; Khayat D
    Bull Cancer; 2005 Jan; 92(1):E1-6. PubMed ID: 15689321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
    Bensmaine M el-A ; Guillot T; Bernal ET; Janot F; Sigal R; Domenge C; Wibault P; Armand JP; Cvitkovic E
    Am J Clin Oncol; 1996 Aug; 19(4):356-62. PubMed ID: 8677904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of mitomycin C, vindesine and cisplatin combined with alpha interferon in advanced non-small cell lung cancer.
    Silva RR; Bascioni R; Rossini S; Zuccatosta L; Mattioli R; Pilone A; Delprete S; Battelli N; Gasparini S; Battelli T
    Tumori; 1996; 82(1):68-71. PubMed ID: 8623510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
    Crinò L; Clerici M; Figoli F; Carlini P; Ceci G; Cortesi E; Carpi A; Santini A; Di Costanzo F; Boni C
    Ann Oncol; 1995 Apr; 6(4):347-53. PubMed ID: 7619749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group.
    Gandara DR; Perez EA; Wold H; Caggiano V; Malec M; Ahn DK; Meyers F; Carlson RW
    Cancer Chemother Pharmacol; 1990; 27(3):243-7. PubMed ID: 2176134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
    Nakano T; Ikegami H; Nakamura S; Kawase T; Nishikawa H; Yokota S; Yoshida M; Tachibana T; Igarashi T; Komuta K; Higashino K
    Br J Cancer; 1996 May; 73(9):1096-100. PubMed ID: 8624270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC).
    Boni C; Savoldi L; Bisagni G; Ceci G; Crinò L; De Lisi V; Di Costanzo F; Lasagni L; Manenti AL; Moretti G; Rondini E; Sassi M; Zadro A
    Eur J Cancer; 1998 Nov; 34(12):1974-6. PubMed ID: 10023325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
    Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial.
    Vansteenkiste J; Vandebroek J; Mariën S; Roex L; Bertrand P; Bockaert J; De Beukelaar T; Deman R; De Muynck P; Ulrichts H
    Lung Cancer; 1995 Dec; 13(3):295-303. PubMed ID: 8719069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.